Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
SPRAVATO ®▽ (esketamine) nasal spray approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder - Hospital Professional News
Study: Esketamine tops quetiapine in treatment-resistant depression
Nasal Ketamine is Here: Spravato and the Controversy | Find Ketamine Infusion Clinics | Ketamine Clinics Directory
Esketamine Nasal Spray
L'eskétamine, un nouvel antidépresseur en spray nasal, approuvé aux Etats-Unis